作者
Peter L Anderson, David V Glidden, Albert Liu, Susan Buchbinder, Javier R Lama, Juan Vicente Guanira, Vanessa McMahan, Lane R Bushman, Martín Casapía, Orlando Montoya-Herrera, Valdilea G Veloso, Kenneth H Mayer, Suwat Chariyalertsak, Mauro Schechter, Linda-Gail Bekker, Esper Georges Kallás, Robert M Grant, iPrEx Study Team
发表日期
2012/9/12
期刊
Science translational medicine
卷号
4
期号
151
页码范围
151ra125-151ra125
出版商
American Association for the Advancement of Science
简介
Drug concentrations associated with protection from HIV-1 acquisition have not been determined. We evaluated drug concentrations among men who have sex with men in a substudy of the iPrEx trial . In this randomized placebo-controlled trial, daily oral doses of emtricitabine/tenofovir disoproxil fumarate were used as pre-exposure prophylaxis (PrEP) in men who have sex with men. Drug was detected less frequently in blood plasma and in viable cryopreserved peripheral blood mononuclear cells (PBMCs) in HIV-infected cases at the visit when HIV was first discovered compared with controls at the matched time point of the study (8% versus 44%; P < 0.001) and in the 90 days before that visit (11% versus 51%; P < 0.001). An intracellular concentration of the active form of tenofovir, tenofovir-diphosphate (TFV-DP), of 16 fmol per million PBMCs was associated with a 90% reduction in HIV acquisition relative to the …
引用总数
20132014201520162017201820192020202120222023202443686796791021101481051148940
学术搜索中的文章